Gyre Therapeutics Quarterly Balance Sheet
NASDAQ: GYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gyre Therapeutics financial position
As of Jun 30, 2026, Gyre Therapeutics reported total assets of $199.3 million, up 30.5% from a year earlier against total liabilities of $34.3 million. Shareholders' equity stood at $107.9 million, or 54.2% of assets. The company held $43.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.26, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Gyre Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 43.29M | 37.50M | 49.19M | 40.40M | 36.49M | 15.04M | 11.81M | 15.87M | 16.10M | 29.79M | 33.51M | 2.23M |
| Short-Term Investments | 14.06M | 12.31M | 15.36M | 19.65M | 17.87M | 14.85M | 14.86M | 9.23M | 9.00M | 7.57M | — | — |
| Receivables | 27.76M | 22.76M | 31.08M | 25.88M | 24.63M | 20.15M | 19.59M | 19.49M | 18.62M | 15.46M | 15.16M | — |
| Inventory | 11.43M | 11.35M | 10.17M | 8.85M | 8.86M | 7.88M | 6.34M | 6.38M | 5.63M | 4.94M | 4.28M | — |
| Total Current Assets | 122.07M | 91.73M | 149.36M | 98.58M | 91.28M | 68.45M | 64.79M | 54.81M | 53.52M | 62.72M | 57.22M | 5.13M |
| Property, Plant & Equipment | 27.28M | 23.57M | 27.55M | 23.61M | 23.40M | 23.52M | 23.88M | 24.44M | 23.67M | 23.56M | 23.29M | — |
| Intangible Assets | 4.53M | 4.63M | 4.73M | 4.85M | 4.96M | 5.08M | 273.00K | 184.00K | 186.00K | 196.00K | 273.00K | — |
| Long-Term Investments | 1.60M | — | 1.59M | — | — | — | 1.60M | — | — | — | — | — |
| Total Assets | 199.25M | 162.01M | 219.76M | 159.38M | 152.65M | 129.79M | 125.41M | 125.24M | 120.93M | 122.01M | 116.54M | 9.96M |
| Accounts Payable | 1.24M | 265.00K | 1.33M | 556.00K | 71.00K | 122.00K | 108.00K | 303.00K | 271.00K | 330.00K | 355.00K | 158.00K |
| Total Current Liabilities | 28.66M | 19.79M | 23.78M | 15.91M | 16.92M | 18.99M | 19.52M | 14.72M | 15.57M | 19.49M | 20.05M | 1.78M |
| Total Liabilities | 34.34M | 25.03M | 31.40M | 21.97M | 23.20M | 25.49M | 27.00M | 26.77M | 27.58M | 33.24M | 38.06M | 6.45M |
| Shareholders' Equity | 107.93M | 101.31M | 62.50M | 101.92M | 92.03M | 68.12M | 63.32M | 63.18M | 60.35M | 56.64M | -15.83M | 3.52M |
| Retained Earnings | -137.96M | -77.67M | -112.60M | -66.70M | -70.31M | -70.75M | -73.45M | -73.35M | -74.48M | -78.01M | -85.54M | -414.72M |
| Net Cash (Debt) | 57.34M | 49.81M | 64.55M | 60.05M | 54.37M | 29.89M | 26.67M | 25.09M | 25.10M | 37.35M | 33.51M | 2.23M |
| Shares Outstanding | 106.03M | 91.34M | 91.31M | 90.89M | 90.82M | 87.64M | 86.31M | 85.77M | 85.54M | 85.42M | 76.60M | 37.98M |
This table shows 12 quarterly periods of Gyre Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow GYRE's reporting calendar. What is a balance sheet?